Palisade Bio Reports Third Quarter Financial Results
15 nov. 2021 07h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help...
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders
22 oct. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic...
Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
09 sept. 2021 08h30 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Reports Second Quarter Financial Results and Provides Business Update
24 août 2021 08h15 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic...
Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center
20 août 2021 09h25 HE
|
Palisade Bio, Inc.
$5.2M invested at $3.45 stock priceFunds to be used to advance clinical development of LB1148Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used...
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
29 juil. 2021 08h15 HE
|
Palisade Bio, Inc.
Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...
Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development
13 juil. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions
15 juin 2021 08h15 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
13 mai 2021 07h00 HE
|
Palisade Bio, Inc.
LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery...
Neuralstem任命Ken Carter博士出任董事會執行主席
19 déc. 2018 02h04 HE
|
Neuralstem, Inc.
美國馬里蘭州日耳曼敦, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 專注於根據神經幹細胞及小分子科技研發神經系統療法的生物製藥公司Neuralstem, Inc.（Nasdaq代碼：CUR）任命Kenneth C. Carter博士出任公司董事會的執行主席，自2019年1月1日起開始生效。Carter博士將接替即將卸任的臨時首席執政官Jim Scully。 ...